Journal of psychoactive drugs
January 1, 2023
Julian Urrutia, Brian T Anderson, Sean J Belouin et al.
21 citations
Combining psychedelic science, contemplative practices, and Indigenous and other traditional knowledge systems in integrative, community-based models of care could transform global health. Both contemplative practices and certain psychedelic substances reliably induce self-transcendent experiences that positively affect health, well-being, and prosocial behavior, and combining them appears synergistic. Traditional knowledge systems offer ethnobotanical expertise and time-tested practices. A decolonized agenda for psychedelic research requires collaborative engagement with traditional knowledge stewards to co-develop evidence-based integrative care accessible to their communities. Health systems could include Indigenous and traditional healers as stakeholders in designing, implementing, and evaluating community-based approaches for safely scaling psychedelic treatments.
Psychopharmacology
May 1, 2022
Sam Craft, Jason A Ferris, Monica J Barratt et al.
19 citations
People who frequently use synthetic cannabinoid receptor agonists (SCRAs) experience a distinct withdrawal syndrome, with sleep problems, irritability, and low mood being the most common symptoms. Among 284 frequent users who had tried to quit, an average of 4.4 withdrawal symptoms occurred after just one day without use. Greater frequency and quantity of SCRA use were linked to more withdrawal symptoms. Compared to high-potency herbal cannabis, SCRAs were rated as having a faster onset, shorter duration of effects, faster tolerance development, and more severe withdrawal. The findings suggest that SCRAs carry a greater risk of problematic use and a more severe withdrawal syndrome than natural cannabis.
Journal of psychopharmacology (Oxford, England)
January 1, 2025
Karen P Barrios, Dean J Connolly, Jason A Ferris et al.
17 citations
Ketamine use has increased globally, particularly among young men, yet emergency medical treatment for its toxicity is rare and often linked to other substance use. Analysis of over 130,000 Global Drug Survey responses found that 5.93% had used ketamine in their lifetime, with 57.70% using it in the past year. Past-year users were typically younger (average age 24.84 years), gay, students, and used other drugs. Among 4,477 past-year users, 120 adverse events occurred, with less than 0.10% requiring emergency medical treatment. The findings indicate frequent use but low harm, highlighting the need for tailored harm reduction and comprehensive screening for substance dependence.
The International journal on drug policy
January 1, 2024
Leigh Coney, Amy Peacock, Aili Malm et al.
2 citations
People who buy MDMA, cocaine, or LSD from cryptomarkets are more likely to have no drug-using social network and to report adverse events requiring medical treatment. Among over 23,000 respondents from more than 70 countries in the 2018 Global Drug Survey, adverse events were low overall (5.2%). After controlling for age, gender, and frequency of use, recent cryptomarket use was associated with a higher likelihood of having no drug-using network for each drug. It was also linked to increased odds of adverse events for cocaine (adjusted odds ratio 1.70) and LSD (adjusted odds ratio 1.58). For those with a network larger than one person, cryptomarket use was still associated with more adverse LSD events. The findings suggest cryptomarket use may increase drug-related harm, but the complex mechanisms require further study.